Transaction · 0001439222-26-000122

Gheuens Sarah

Gheuens Sarah, CMO, reported a transaction classified as exercise at AGIOS PHARMACEUTICALS, INC. involving 500.000000 shares for an estimated $12505.00. Reported holdings after the transaction were 55145.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MCMO
AGIOAGIOS PHARMACEUTICALS, INC.
Trade date
Oct 22, 2026
Filing date
Oct 23, 2026
View on SEC Insider profile
Estimated value$12.5kShares × reported price
Shares traded500$25.01 per share
Holdings after55.1kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

AGIO price since this filing

Daily closing prices, with the filing date and available return windows
AGIO · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +0.0%1w ago +0.0%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001439222-26-000122
Common stock
Transaction date
Oct 22, 2026
Filed Oct 23, 2026, 08:05 PM · 1d delay
Shares
500 sh
$25.01 per share
Estimated value
$12.5k
Computed from shares × price
Holdings after
55,145 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

  2. F2

    The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.52 to $37.55. The reporting person undertakes, upon request by the staff of th…

  3. F3

    This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments th…

Original filing · 0001439222-26-000122
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

AGIO